Last updated: February 26, 2026
What is the Drug NDC 43547-0459?
NDC 43547-0459 corresponds to Methylphenidate Hydrochloride Extended-Release (ER) Capsule. It is indicated for ADHD and narcolepsy management. The drug is marketed primarily under the brand Concerta, with generic versions also available.
Market Overview
Production and Market Penetration
- Manufacturers: Johnson & Johnson (original), multiple generic producers (e.g., Actavis, Mylan, Teva).
- Market Share: Concerta held approximately 60% of the methylphenidate extended-release capsule market in 2022. Generic versions control roughly 40%.
- Pricing Dynamics: Patent expiration in 2018 led to increased generic competition, resulting in substantial price declines.
Regulatory Status
- FDA Approval Date: 2000.
- Patent Expiry: 2017, facilitating generic market entry.
- Generic Approvals: Multiple generics since 2017, with varying formulations and manufacturing processes.
Market Size
- The US ADHD medication market was valued at roughly $4.2 billion in 2022.
- Methylphenidate ER capsules account for around 25% of this market, approximately $1 billion annually.
- Annual US unit sales estimated at 20 million prescriptions, averaging around 30 capsules per prescription.
Current Usage Trends
- Steady growth driven by increased ADHD diagnosis.
- Shift from branded to generic formulations reduces per-unit price but expands total volume.
Price Points and Historical Trends
| Year |
Brand (Concerta) Avg Price per 30-Count Bottle |
Generic Avg Price per 30-Count Bottle |
| 2017 |
$270 |
$180 |
| 2019 |
$250 |
$150 |
| 2021 |
$240 |
$130 |
| 2022 |
$235 |
$125 |
- Prices declined an average of 4-6% annually post-generic entry.
- Retail prices vary based on pharmacy discounts, insurance coverage, and pharmacy benefit managers (PBMs).
Price Projections (Next 2-5 Years)
Assumptions
- Continued generic competition maintains downward pressure.
- No major patent protections or exclusivity extensions.
- Slight inflation-adjusted price stabilization due to manufacturing costs.
- Possible introduction of new formulations or delivery methods.
Projections
| Year |
Brand Price Estimate |
Generic Price Estimate |
Key Factors |
| 2023 |
$230 |
$120 |
Competition stabilizes prices, slight decline |
| 2024 |
$228 |
$115 |
Increased competition, operational efficiencies |
| 2025 |
$226 |
$110 |
Market saturation, slow price reduction |
| 2026 |
$224 |
$105 |
Mature generic market with minimal decline |
Note: Prices are approximations based on historical trends and market dynamics.
Revenue Impact
- A 2% annual price decline on generics combined with stable volume suggests a steady revenue stream, assuming demand remains constant.
- Branded product's revenue diminished after patent expiry but maintains premium pricing for special formulations.
Competitive Analysis
Key Competitors
- Concerta (J&J): Market leader with brand loyalty.
- Generic providers: Multiple companies offering bioequivalent products at lower prices.
- Alternative formulations: Immediate-release methylphenidate and other stimulants like amphetamines.
Market Share Shifts
- Generic methylphenidate ER capsules increased share from 20% in 2017 to 40% in 2022.
- Entry of new formulations (e.g., Concerta OROS alternative) slightly shifts demand.
Regulatory and Policy Influences
- Pricing regulations: PBM negotiations and formulary placements influence actual patient costs.
- Rebates and discounts: Affect net pricing and revenues for manufacturers.
- Potential patent litigation or exclusivity extensions could impact future pricing strategies.
Conclusions
- The methylphenidate ER capsule market is mature, with sustained demand due to consistent ADHD diagnosis rates.
- Price erosion continues under generic competition, with average prices decreasing by approximately 5% annually.
- Price projections suggest stabilization at lower levels for the foreseeable future, with minimal upward trend absent new formulations or policies.
Key Takeaways
- Market dominance by generic versions has driven prices down significantly from pre-2017 levels.
- Continued generic entry and competitive pressures are expected to sustain low or declining average prices over the next five years.
- The overall market remains substantial, with stable demand supporting volume sales.
- Pricing strategies should focus on maximizing revenue amid low-margin generic competition.
- Policy changes, patent litigations, or formulation innovations could influence future pricing.
FAQs
1. How does the patent status affect current pricing?
Patent expiration in 2017 allowed multiple generics to enter the market, leading to substantial price declines. No current patent protections are in place for the extended-release capsule.
2. What is the expected impact of new formulations?
New formulations or delivery methods could temporarily increase prices or market share but are unlikely to significantly alter the long-term pricing trend unless they replace existing products.
3. How do insurance and PBM negotiations influence net prices?
Insurance discounts, rebates, and PBM formularies impact the actual cost to payers and patients, often reducing the retail price received by manufacturers.
4. What are the primary competitors for NDC 43547-0459?
Other methylphenidate formulations (immediate-release, osmotic-controlled release) and alternative stimulants like amphetamines.
5. How might policy changes affect future prices?
Potential regulatory changes targeting drug pricing transparency, rebates, or patent extensions could impact prices, either increasing or decreasing them depending on the policy approach.
References
[1] IQVIA. (2022). US Prescription Market Data.
[2] FDA. (2017). Summary of Patent and Exclusivity Data.
[3] MedTrack. (2022). Market Share and Pricing Reports.
[4] GoodRx. (2023). Average Retail Prices for Methylphenidate.
[5] Statista. (2023). ADHD Medication Market Valuation.
